Back to Search
Start Over
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma
- Source :
- AIDS. 24:2408-2412
- Publication Year :
- 2010
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2010.
-
Abstract
- In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
- Subjects :
- Adult
Male
medicine.medical_treatment
Immunology
Integrase inhibitor
HIV Infections
Pharmacology
Neutropenia
Vinblastine
hemic and lymphatic diseases
medicine
Humans
Immunology and Allergy
HIV Protease Inhibitor
Drug Interactions
Protease inhibitor (pharmacology)
Aged
Ritonavir
Protease
business.industry
HIV Protease Inhibitors
Middle Aged
Hodgkin's lymphoma
medicine.disease
Hodgkin Disease
Settore MED/15 - MALATTIE DEL SANGUE
Infectious Diseases
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 02699370
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- AIDS
- Accession number :
- edsair.doi.dedup.....f40e8263372da8ef7d8563f5a343a614